Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

September 21, 2026

Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin...

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

Performance

52-Week Range 94.2% below 52-week high

0.1610

0.1452W Low 2.7852W High

1 Week 4.4% below 1-week high

0.151W Low 0.171W High

Medicus Pharma Ltd. - Common Stock (MDCX) traded between $0.14 and $2.78 over the past 52 weeks and last traded at $0.16, 94.2% below its 52-week high. Over the past week it ranged between $0.15 and $0.17.

Past 12 Months

+5.9%

-6.4%

-65.0%

-67.2%

-89.9%

-93.6%

1W +$0.01

1M -$0.01

3M -$0.30

6M -$0.33

YTD -$1.44

1Y -$2.36

MDCX was -93.6% over the past year, -67.2% over six months, -89.9% year to date, +5.9% in the last week.

12 Months vs Market

MDCX

-93.6%

DIA

+9.5%

SPY

+14.6%

QQQ

+23.3%

IWM

+14.1%

Over the past 12 months MDCX returned -93.6% versus DIA (Dow) +9.5%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +23.3% and IWM (Russell 2000) +14.1%.

Volume & Liquidity 0.01× 3-mo avg

Today 31,867 3-mo avg 4.3M

1.4M

6.0M

4.3M

4.2M

YTD

4.0M

3.1M

MDCX most recently traded 31,867 shares against a 3-month average daily volume of 4.3M.

More News

Unusual volume stocks are being observed in Thursday's session. ↗

September 10, 2026

Via Chartmill

September 10, 2026

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

Unusual volume stocks in Tuesday's session ↗

September 08, 2026

Via Chartmill

September 08, 2026

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

September 03, 2026

Via Chartmill

Check out the stocks that are attracting the most attention and driving market activity. ↗

September 03, 2026

Via Chartmill

Thursday's session: top gainers and losers ↗

September 03, 2026

Via Chartmill

Gapping stocks in Thursday's session ↗

September 03, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

September 03, 2026

Via Chartmill

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

August 03, 2026

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

July 31, 2026

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

July 27, 2026

New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings

July 25, 2026

From New to The Street

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Top movers in Friday's after hours session ↗

July 24, 2026

Via Chartmill

July 16, 2026

New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 13, 2026

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

July 13, 2026

Via Chartmill

July 04, 2026

From New to The Street

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

June 22, 2026

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

June 20, 2026

From New to The Street

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

June 15, 2026

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

June 12, 2026